A patient-derived explant (PDE) model of hormone-dependent cancer. by Centenera, Margaret M et al.
A patient-derived explant (PDE) model of
hormone-dependent cancer
Margaret M. Centenera1,2, Theresa E. Hickey3, Shalini Jindal3, Natalie K. Ryan1,2,
Preethi Ravindranathan4, Hisham Mohammed5, Jessica L. Robinson6, Matthew J. Schiewer7,
Shihong Ma4, Payal Kapur4, Peter D. Sutherland8, Clive E. Hoffmann9, Claus G. Roehrborn4,
Leonard G. Gomella10, Jason S. Carroll6, Stephen N. Birrell9, Karen E. Knudsen7, Ganesh V. Raj4,
Lisa M. Butler1,2 and Wayne D. Tilley1,3
1 Freemasons Foundation Centre for Men’s Health, Adelaide Medical School, University of Adelaide, SA, Australia
2 South Australian Health and Medical Research Institute, Adelaide, SA, Australia
3 Dame Roma Mitchell Cancer Research Laboratories, Adelaide Medical School, University of Adelaide, SA, Australia
4 Department of Urology, UT Southwestern Medical Center at Dallas, TX, USA
5 Knight Cancer Early Detection Advanced Research Center, Oregon Health and Science University, Portland, OR, USA
6 Transcription Factor Laboratory, Cancer Research UK, Cambridge Institute, Cambridge University, UK
7 Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA, USA
8 Urology Unit, Surgical Specialties Service, Royal Adelaide Hospital, SA, Australia
9 Breast Clinic, Burnside War Memorial Hospital, Toorak Gardens, SA, Australia
10 Department of Urology, Thomas Jefferson University, Philadelphia, PA, USA
Keywords
ex vivo culture; patient-derived explant;
preclinical tumor model
Correspondence
M. M. Centenera, Adelaide Medical School,
University of Adelaide, c/o Cancer Theme,
Level 5N, SAHMRI, PO Box 11060,
Adelaide, SA 5001, Australia
Fax: +61 8 8128 4004
Tel: +61 8 8128 4361
E-mail: margaret.centenera@adelaide.edu.au
and
W. D. Tilley, Dame Roma Mitchell Cancer
Research Laboratories, University of
Adelaide, Adelaide Health and Medical
Sciences Building, North Terrace, Adelaide,
SA 5000, Australia
Tel: +61 8 8313 7861
E-mail: wayne.tilley@adelaide.edu.au
(Received 17 May 2018, revised 25 June
2018, accepted 25 June 2018, available
online 16 August 2018)
doi:10.1002/1878-0261.12354
Breast and prostate cancer research to date has largely been predicated on
the use of cell lines in vitro or in vivo. These limitations have led to the
development of more clinically relevant models, such as organoids or mur-
ine xenografts that utilize patient-derived material; however, issues related
to low take rate, long duration of establishment, and the associated costs
constrain use of these models. This study demonstrates that ex vivo culture
of freshly resected breast and prostate tumor specimens obtained from sur-
gery, termed patient-derived explants (PDEs), provides a high-throughput
and cost-effective model that retains the native tissue architecture, microen-
vironment, cell viability, and key oncogenic drivers. The PDE model pro-
vides a unique approach for direct evaluation of drug responses on an
individual patient’s tumor, which is amenable to analysis using contempo-
rary genomic technologies. The ability to rapidly evaluate drug efficacy in
patient-derived material has high potential to facilitate implementation of
personalized medicine approaches.
Abbreviations
ANOVA, analysis of variance; AR, androgen receptor; BrdU, 5-bromo-2-deoxyuridine; ChIP, chromatin immunoprecipitation; E2, estradiol;
ERa, estrogen receptor alpha; H&E, hematoxylin and eosin; LHRH, luteinizing hormone-releasing hormone; PDE, patient-derived explant;
PDX, patient-derived xenograft; PGR, progesterone receptor; PSA, prostate-specific antigen; RARA, retinoic acid receptor-a; RNAi, RNA
interference; shRNA, short hairpin RNA.
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1. Introduction
Preclinical models that accurately replicate the native
architecture and microenvironment of primary human
tumors are urgently needed to improve our under-
standing of basic tumor biology and to facilitate the
development of improved therapeutic approaches
(Thompson et al., 2008). The use of immortalized
human cell line models for investigating novel thera-
pies in vitro or in vivo is convenient but also a major
reason for the high failure of new drugs entering clini-
cal trials. To move toward more clinically relevant
model systems, researchers have adopted patient-
derived approaches such as organoids (Drost et al.,
2016; Gao et al., 2014) and xenografts (PDX) (Lawr-
ence et al., 2013; Wang et al., 2005; Whittle et al.,
2015). We report an alternative approach of culturing
freshly resected breast and prostate cancer tissue as
patient-derived explants (PDE). Ex vivo culture of
human prostatic tissue has been used since the 1970s
with varying degrees of success, and protocols ranging
from total immersion of tissue pieces in medium to
culture of tissue pieces or slices on grid or sponge scaf-
folds, reviewed by Centenera et al. (2013). Despite this
long-standing history and general acknowledgment of
the potential of ex vivo cultured tissues to increase the
clinical relevance of laboratory research (Centenera
et al., 2013; Kim, 2005; Pretlow et al., 1995; Ris-
bridger et al., 2018; Vescio et al., 1991), the PDE
method has not been widely adopted to study solid
tumors. The purpose of this study was to highlight
advantages of the PDE model and demonstrate how it
can be applied to interrogate hormone-dependent can-
cers such as those of the breast and prostate.
2. Materials and methods
2.1. Ethical approval for research using human
tissue
All research conducted in this study conformed to the
standards set by the Declaration of Helsinki.
2.1.1. Australia
The use of freshly resected human tissue samples for
this study was approved by the Human Research
Ethics Committees of the University of Adelaide, the
Royal Adelaide Hospital, and Burnside War Memorial
Hospital. All material is collected with written
informed consent from patients, and data are de-iden-
tified according to National Health and Medical
Research Council of Australia guidelines for human
research. Prostate tissues were collected as part of the
Australian Prostate Cancer BioResource.
2.1.2. United States
Prostate tissues from UT Southwestern Medical Center
at Dallas and Thomas Jefferson University hospitals
were obtained with written informed consent from
patients undergoing radical prostatectomy for high-
volume cancer, under Institutional Review Board-
approved protocols for the respective institutions.
Clinical characteristics and histopathology of
patients who donated tissue to this study are outlined
in Table S1.
2.2. PDE culture of solid tumors
The PDE technique utilized in this study employs a gela-
tin sponge platform (Centenera et al., 2013) (Fig. 1A).
This method was selected for two key reasons: firstly,
the use of a substrate for explant culture prevents cellu-
lar outgrowth that is frequently observed when tissues
are cultured without support and completely submerged
in media (Pretlow et al., 1995; Varani et al., 1999); sec-
ondly, the gelatin sponge used in this study is a commer-
cial medical device developed for hemostasis (Ferrosan,
2014) that is readily available, cost-effective, and simple
to use, making the method feasible for widespread
adoption in translational cancer research laboratories.
Figure 1A illustrates the PDE method using prostate
tumors as an example. Following surgical tissue
removal, the surgeon or clinical pathologist resects a
sample of the presumed malignant or nonmalignant
region and the specimen is transported to the research
laboratory in cold phosphate-buffered saline on ice,
typically within 1–2 h of surgery. Under sterile condi-
tions, tissue was placed onto the lid of a 10-cm plate
along with the saline it was transported in. Using a sur-
gical blade, a 1-mm-thick longitudinal section of the
tissue sample is cut and placed into neutral-buffered
formalin for paraffin embedding. This tissue is called
the Day 0 sample and is used to determine the cancer
content of the tissue following staining with hema-
toxylin and eosin (H&E). The remaining tissue is dis-
sected into 1-mm3 pieces, called explants, and placed in
triplicate or quadruplicate (depending on amount of
tissue received) on top of a media-soaked gelatin
sponge (Ethicon; Johnson & Johnson, Somerville, NJ,
USA) inside the wells of a 24-well plate containing
500 lL RPMI 1640 medium containing 10% fetal
bovine serum, 19 antimycotic/antibiotic solution,
0.01 mgmL1 hydrocortisone, and 0.01 mgmL1 insu-
lin. The appropriate vehicle, treatment, or shRNA was
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added directly to the media inside the appropriate tis-
sue culture well at the indicated concentrations, allow-
ing direct comparison of treatments and controls.
Explants were cultured at 37 °C and 5% CO2 for vari-
ous time points and then formalin-fixed and paraffin-
embedded, snap-frozen, or preserved in RNAlater
(Invitrogen, San Diego, CA, USA) depending on the
desired downstream analysis. For assessment of BrdU
incorporation, BrdU (10 lM) was added to the culture
medium 2 h (prostate) or 24 h (breast) prior to harvest.
In our collective experience, all tissues containing
epithelial cells can successfully be cultured, and the lim-
iting factor for analysis is instead the presence of suffi-
cient numbers of epithelial (for benign tissue studies) or
malignant cells (for cancer tissue studies). For this rea-
son, routine hematoxylin and eosin (H&E) staining of
all Day 0 and cultured tissues is an essential part of
our protocol to confirm the presence and approximate
percentage of benign/malignant cells within the speci-
mens before proceeding with further analyses. Between
the three prostate cancer laboratories, our collective
experience indicates that approximately 10% of tissues
from high-volume disease and 20–30% of tissues from
low-volume disease do not contain malignant cells, and
this is largely due to sampling.
2.3. Immunohistochemistry
Immunohistochemical staining was performed on 2- to
4-lm sections that were deparaffinized, rehydrated, and
blocked for endogenous peroxidase before being sub-
jected to heat-induced epitope retrieval. Breast tissues
were additionally treated to block for endogenous bio-
tin. Sections were blocked and incubated with the
appropriate primary and secondary antibodies, then
developed using 3-30-diaminobenzidine chromogen, and
counterstained with hematoxylin. Appropriate positive
and negative controls were included in all runs.
Table S2 lists pertinent information for all antigens.
Immunostaining in the Tilley laboratory was per-
formed manually, and in the Raj laboratory, immunos-
taining was performed on the DAKO autostainer
(DakoCytomation, Carpinteria, CA, USA). Tissues
cultured by the Knudsen laboratory were stained by
the Raj laboratory. The percent positivity and intensity
of nuclear staining for each antigen were quantified
manually by an independent pathologist or observer,
who was blinded to the treatments/conditions.
2.4. RNA extraction
Tissues preserved in RNAlater (Qiagen, Hilden, Ger-
many) were homogenized in ice-cold PBS with a Pre-
cellys 24 Tissue Homogenizer (Bertin Technologies,
Montigny-le-Bretonneux, France), and RNA was
extracted using Trizol according to the manufacturer’s
instructions. DNAse treatment was performed using
the TurboDNase kit (Ambion, Austin, TX, USA)
according to manufacturer’s instructions. RNA was
quantified using a Nanodrop 1000 spectrophotometer
(Thermo Fisher Scientific, Waltham, MA, USA). Rev-
erse transcription was performed on 400 ng total RNA
using the iScript kit (Bio-Rad Laboratories, Hercules,
CA, USA) according to manufacturer’s instructions.
2.5. Quantitative real-time PCR
qPCR was performed using 2 lL of cDNA from
whole tissue extracts and SYBR green for prostate
explants, and gene-specific TaqMan assays were per-
formed for breast explants. Primers and assay IDs are
listed in Table S3. Relative gene expression was calcu-
lated using the DCt method. Expression of PSA in
prostate explants was normalized to PPIA, L19,
TUBA1B, ALAS1, and GAPDH. Progesterone recep-
tor (PGR) expression in breast explants was normal-
ized to IPO8 and PUM1.
2.6. Ablation of AR by shRNA
The shAR and shControl lentiviral constructs were
packaged using Lenti-X HT (Open Biosystems, Dhar-
macon Inc., Lafayette, CO, USA) according to the
manufacturer’s instructions and added to the tissue
Fig. 1. PDE culture sustains tissue morphology, viability, and endocrine signaling. (A) PDE tissue culture method. (i) Following surgery, a
core of tumor tissue is removed by a pathologist (tumor area demarcated by broken white line), (ii) the tumor sample is dissected into 1-
mm3 fragments, (iii) cultured in 24-well plates on a gelatin sponge sitting in media, allowing direct comparison of treatments in matched
tumor tissue, and (iv) schematic diagram of PDE setup. (B) Representative hematoxylin and eosin staining of PDEs from primary prostate
and breast tumors, showing maintenance of gross morphology following 6 days in culture. Arrows indicate examples of tumor cells and
surrounding stroma. (C) HIF1a staining from three independent laboratories showed no significant difference in prostate cancer tissue
oxygenation after 6 days of PDE culture. Staining intensity was manually assessed by a single pathologist (P. Kapur). Data are presented as
mean  SEM, n = 3. (D) Expression and signaling of steroid receptors critical for prostate and breast carcinogenesis were maintained in
PDEs cultured in complete media for 6 days, as demonstrated by immunostaining for AR and the AR-regulated protein PSA in prostate
PDEs, and ERa and the ERa-regulated protein PGR in breast cancer PDEs. Scale bars represent 50 lm.
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culture medium for 48 h. Lentiviral media was then
removed and replaced with fresh media containing no
lentivirus and cultured for an additional 48 h. Tissues
were harvested and formalin-fixed prior to immunohis-
tochemistry staining for androgen receptor (AR) and
prostate-specific antigen (PSA) as described above.
2.7. Chromatin immunoprecipitation followed by
massively parallel DNA sequencing (ChIP-seq)
Breast cancer PDEs cultured in complete medium con-
taining vehicle (EtOH; 0.1%), 17b-estradiol (E2; 10 nM),
or synthetic PGR agonist R5020 (10 nM) for 72 h were
harvested, crosslinked, and processed for ChIP-seq anal-
ysis as described previously (Ross-Innes et al., 2012).
The estrogen receptor alpha (ERa) HC-20 antibody
(Santa Cruz Biotechnologies, Dallas, TX, USA) was
used for immunoprecipitation of ERa from PDE tissue
lysates. Sequences generated by an Illumina HiSeq 2000
were processed by the Illumina analysis pipeline version
1.6.1 and aligned to the Human Reference Genome
(hg19) using BWA version 0.5.5 (Li and Durbin, 2009).
Reads were filtered by removing those with a BWA
alignment quality score less than 15. Enriched ERa
binding regions were identified by comparing ERa ChIP
DNA samples to total ChIP input DNA. ER ChIP-
sequencing was then performed from each PDE tissue
and treatment. Peak calling was performed using
MACS2 version 1.4.0rc2 (Zhang et al., 2008).
2.8. Statistical analysis
Data are displayed as the mean  standard error. Dif-
ferences were determined using Student’s t-test or one-
way analysis of variance (ANOVA). The correlation
between Ki67 and PSA expression was analyzed using
the Spearman correlation test with an accompany-
ing P value. All statistics and generation of heat map
were performed using GRAPHPAD PRISM Software ver-
sion 7.02 (GraphPad Software, La Jolla, CA, USA). A
P-value ≤ 0.05 was considered statistically significant.
3. Results
3.1. Morphology, viability, and molecular
signaling are sustained in PDEs
Histopathological evaluation of tissue architecture and
cellular appearance demonstrated that the morphology
of PDEs cultured for up to 6 days on gelatin sponges
is consistent with the original, uncultured (i.e., Day 0)
tumor tissue, as illustrated by representative H&E
staining of prostate cancer and breast cancer (Fig. 1B).
Tumor cells are present in the surrounding stroma,
demonstrating maintenance of the tumor microenvi-
ronment (Fig. 1B). Immunohistochemical staining for
the hypoxia-inducible factor (HIF)-1a showed no evi-
dence of hypoxia in PDEs cultured using the sponge
method (Fig. 1C). Importantly, equivalent HIF-1a
staining was observed in prostate tumors cultured in
three independent laboratories (Fig. 1C) and evalua-
tion of serial sections of individual tissues indicated no
discernible difference in histology or antigen staining
between the air or sponge interface (data not shown).
The AR and ERa are critical drivers of prostate and
breast cancer, respectively; therefore, AR and ERa
were assessed as examples of major oncogenic signaling
pathways in the PDE model. Epithelial cell positivity
for immunoreactive AR and ERa was sustained within
malignant prostate and breast PDEs, respectively, for
up to 6 days in complete media (Fig. 1D). Expression
of the androgen-regulated protein, PSA, and the estro-
gen-regulated protein PGR, indicative of functional sig-
naling by AR and ERa, respectively, was also evident
after 6 days of culture (Fig. 1D).
3.2. Proliferative capacity of PDE tumor tissue
Cellular uptake of the thymidine analog 5-bromo-2-
deoxyuridine (BrdU; Fig. 2A) and its nucleoside
analog 5-ethynyl-20-deoxyuridine (Fig. S1) from the
culture media was observed in a subset of prostate
tumors, indicating that cultured tissues have the capac-
ity for de novo proliferation. BrdU uptake was evident
throughout the PDE samples (Fig. 2A) and was con-
cordant with Ki67 positivity (Fig. 2B). Ki67 positivity
in breast and prostate explant tissues was investigated
further to assess suitability of the PDE model to evalu-
ate proliferative responses to hormonal stimuli, growth
factors, or therapeutic agents. The number of Ki67-
positive epithelial cell nuclei (i.e., the cellular prolifera-
tive index) in Day 0 tissues ranged from 0 to 16% and
increased to a range of 0 to 43% (P < 0.05) in matched
tissues after 48 h of culture and remained stable for at
least 96 h (Fig. 2C). The time-dependent increase in
proliferation observed here and in previous organ-
otypic culture models (Nevalainen et al., 1993; Olbina
et al., 1998) is likely due to growth-promoting factors
in the media or to the release of an inhibitory serum
influence that was present in vivo, but absent ex vivo.
3.3. Modulation of AR signaling in prostate
cancer PDEs
AR is the driving transcription factor in prostate can-
cer and the primary therapeutic target for systemic
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treatment. To demonstrate modulation of this critical
signaling pathway, a lentiviral-based shRNA approach
was used for isogenic suppression of AR gene
expression. Lentiviral transduction of cultured prostate
PDEs with an AR-directed shRNA for 48 h decreased
the steady-state protein levels of AR by approximately
Fig. 2. Proliferative capacity of PDEs. (A) De novo proliferation of tumor cells in PDE cultured tissues is demonstrated by BrdU uptake in a
representative prostate cancer explant. (B) The distribution of BrdU uptake is similar to expression of the proliferative marker Ki67 as shown
in a representative prostate cancer PDE. (C) Representative images and quantitation of Ki67 immunostaining in prostate (n = 9) and breast
(n = 8) tissue at Day 0 and in PDEs cultured for up to 96 h in complete media. *ANOVA: Day 0 versus time points, P = 0.0007 for prostate;
P = 0.0013 for breast. All scale bars represent 50 lm.
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50% (Fig. 3A). Importantly, AR inhibition resulted in
a 40% decrease in expression of the AR-regulated pro-
tein PSA (Fig. 3A), which demonstrates that the AR
signaling pathway is functional in PDE tissues.
Clinical inhibition of the AR signaling pathway is
achieved through androgen deprivation therapy or AR
antagonists (Attard et al., 2011). To demonstrate
capacity of the PDE model for evaluating therapeutics,
prostate cancer PDEs were treated with the clinically
used AR antagonist bicalutamide. Proliferative
response was assessed using the immunohistochemistry
marker Ki67, with a response considered significant
when treatment induced a change from vehicle of
≥ 25%. Proliferative responses were observed after
only 48 h of culture; therefore, this time point was
selected to allow short-term, high-throughput preclini-
cal testing to be performed. Similar to Fig. 2C, a large
range of baseline Ki67 (2-58%) was observed across
the cohort (Fig. 3B). In prostate cancer PDEs cultured
in the presence of 10 lM bicalutamide for 48 h, the
proliferative index was reduced in 10/23 tissues (44%),
increased in 6/23 tissues (26%), and had no significant
effect on proliferation in 7/23 tissues (30%) compared
to vehicle-treated PDEs (Fig. 3B). Similar heterogene-
ity in response was observed with the newer generation
antagonist enzalutamide in a smaller, independent
cohort of PDEs (Fig. S2). A change in apoptosis was
not observed in PDEs cultured for 48 h with 10 lM
bicalutamide (Fig. 3C). Collectively, these findings
illustrate the heterogeneity of clinical samples and
demonstrate the importance of using a model that
reflects this natural variation when evaluating solid
tumors. A critical aspect of this research will be relat-
ing the observed heterogeneity with clinical outcomes
of these patients, but we were unable to assess this in
the current study. To date, only one patient (Fig. 3A
patient no. 18) from our cohort of predominantly low-
to-intermediate risk patients (median follow-up time of
48.3 months; range 23–64.4 months) has experienced
biochemical recurrence (BCR). This is consistent with
the reported 5-year BCR rate of 10–20% in low-to-
intermediate risk patients undergoing robotic-radical
prostatectomy (Diaz et al., 2015) and highlights the
need for longer-term follow-up to correlate PDE
results with individual patient outcomes. A more feasi-
ble clinical context to ascertain whether PDE culture is
correlated with clinical outcome is neoadjuvant clinical
trials that allow direct comparison of pre- and post-
treated tumors.
In a subset of 12 PDEs from Fig. 3B, where suffi-
cient matched tissue was available to extract RNA,
changes in PSA gene expression in response to
bicalutamide treatment were evaluated by qPCR. Simi-
lar to Ki67, heterogeneity in PSA response to bicalu-
tamide was observed across the 12 explants (Fig. 3D).
Importantly, in 10/12 tissues Ki67 positivity and PSA
expression increased or decreased concordantly,
demonstrating a significant positive association
(r = 0.657; P = 0.0238; Fig. 3E). Transcript analysis of
additional prototypical AR-regulated genes FKBP5,
KLK2, NKX3.1, and TMPRSS2 shows a similar pat-
tern of expression to PSA and Ki67 (Fig. 3E), indicat-
ing general inhibition of androgen signaling by
bicalutamide in prostate cancer PDEs. No correlation
was observed between proliferative response and
tumor grade, stage, or presurgery serum PSA. How-
ever, we acknowledge that a larger range of samples
may be required to determine this conclusively as the
majority of our specimens were of Gleason grade 7,
stage PT3A/B, and PSA < 10 (Table S1).
3.4. Analysis of ERa signaling in breast cancer
explants
Estradiol (E2)-activated ERa binds to cis-regulatory
elements of target genes such as the PGR (Ross-Innes
et al., 2012). Candidate gene analyses performed on
RNA extracted from ERa-positive PDEs (n = 14) cul-
tured for 24 h with E2 revealed a range of responses
to hormone treatment. E2 stimulation decreased PGR
expression by ≥ 50% in 6/14 tissues (43%), increased
PGR expression by ≥ 50% in 5/14 tissues (36%), and
had no significant effect on PGR in 3/14 tissues (21%)
compared to the matched vehicle controls (Fig. 4A).
To further investigate ERa signaling, we used ChIP-
seq to evaluate E2-treated breast cancer PDEs and
Fig. 3. Modulation of AR signaling in prostate cancer PDEs. (A) Steady-state protein levels of AR and the AR-regulated protein PSA were
knocked down in prostate cancer PDEs (n = 3) cultured in media containing lentiviral-based shRNA directed against AR (shAR) compared
with scrambled control (shCON). Scale bars represent 50 lm. (B) Quantitation and representative images of Ki67 immunostaining in PDEs
derived from 23 patients following 48 h culture with vehicle control or bicalutamide (10 lM). A response to bicalutamide was considered
significant when treatment induced a change from vehicle of ≥ 25%. Scale bars represent 50 lm. (C) Quantitation and representative
images of cleaved caspase-3 immunostaining in PDEs derived from 23 patients following 48-h culture with vehicle control or bicalutamide
(10 lM). Data are presented as mean  SEM. Scale bars represent 50 lm. (D) Water fall plot of percent change in PSA gene expression
and Ki67 immunostaining from a subset of PDEs from (A) treated with vehicle control or bicalutamide (n = 12). (E) Scatterplot of the data
from D showing a positive correlation between Ki67 and PSA with Spearman’s r = 0.657 (P < 0.05). (F) Heat map visualization of qRT-PCR
analysis of classic AR-regulated transcripts in bicalutamide-treated PDEs compared to vehicle (n = 12).
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compared whole-genome ERa binding events with
primary breast cancer tissues and traditional breast
cancer models, including the most commonly used
ERa-positive breast cancer cell line, MCF7, grown
in vitro or in vivo as xenografts. Figure 4B depicts an
example ERa binding site shared by all models [reti-
noic acid receptor-a (RARA)], a binding site identified
in patient-derived tissues only (SLCO5A1), and bind-
ing sites identified in cell line models only (50 kb to
TOB1/SPAG9). These findings clearly highlight how
cell line models do not accurately represent clinical
breast cancer and the importance of utilizing tissue-
based models for interrogation of mechanisms of car-
cinogenesis.
We have previously shown that PGR is not only an
ERa-target gene but is also an ERa-associated protein
that can reprogram ERa DNA binding and transcrip-
tional responses in breast cancer and, importantly,
used the PDE model to study the transcriptome and
growth effects of this ERa reprogramming by PGR
(Mohammed et al., 2015; Singhal et al., 2016). To fur-
ther investigate these findings, herein we report suc-
cessful ERa ChIP-seq in ERa-positive breast cancer
PDEs cultured with E2 in the presence or absence of
synthetic PGR agonist R5020. The number of ERa
binding events in each E2-treated and E2 + R5020-
treated PDE is shown in Table S4. ERa binding could
be mapped in all PDEs, but total peak intensity and
the number of identified binding events differed
between PDEs and treatments. To systematically quan-
tify these observations, consensus ERa chromatin
binding sites were compiled for each treatment by
including peaks found in at least two of the three
cases. Under estrogenic conditions alone, there were a
total of 22 658 consensus ERa binding sites, and
under estrogenic conditions with R5020 supplementa-
tion, there were a total of 34 051 consensus sites, with
18 790 shared sites between the two conditions
(Fig. 4C). Further 3868 and 15 261 ERa binding sites
were identified to be specific to either estrogen alone
or estrogen plus R5020 treatment, respectively
(Fig. 4C). Representative images of ERa chromatin
binding at the RARA-positive control locus demon-
strate robust peaks common to both treatment condi-
tions (Fig. 4D, upper panel), as well as binding peaks
specific to individual hormone treatments, such as
those observed 10 kb upstream of the nuclear receptor
coactivator 3 (NCOA3) locus (Fig. 4D, lower panel).
4. Discussion
Patient-derived explant tissue culture on a gelatin scaf-
fold retains many features of human solid tumors,
including the native microenvironment and cellular
interactions that are critical for carcinogenesis but are
lacking in many preclinical models. This study demon-
strates that PDEs are not only viable in culture but
can be manipulated using hormones, siRNA, or cancer
drugs and that the response to those interventions can
be assessed using an array of techniques, including
immunohistochemistry, real-time qRT-PCR, and geno-
mewide molecular analyses of cistromes. The PDE
method is robust, as shown through observations of
sustained tissue morphology, viability, and mainte-
nance of critical cancer-related signaling pathways in
independent laboratories. It is also applicable to multi-
ple solid tumor types; to date, the methodology has
successfully been applied to all cancers tested, includ-
ing some not represented in the current study (ovary,
endometrium, renal, sarcoma; personal communica-
tion). The de novo cellular proliferation observed in
cultured tissues indicates that the system is not static
and makes this a particularly useful model to assess
the growth inhibitory activity of new or emerging ther-
apeutic agents, as demonstrated by our respective
teams using PDEs from prostate cancer and breast
cancer (Centenera et al., 2012; Comstock et al., 2013;
Dean et al., 2012; de Leeuw et al., 2015; Schiewer
et al., 2012).
One of the most exciting aspects of the PDE model
is the potential to uncover information about the
diversity of tumor biology that is not possible using
cell lines or cell line xenografts due to their clonality.
Observed changes in PSA and PGR expression in
prostate and breast tumors as markers of AR and
ERa signaling, respectively, reflected the natural tumor
heterogeneity observed clinically for each tumor type
examined (Arnedos et al., 2013). Variation in PSA
response to bicalutamide, the most common antagonist
used in locally advanced disease (Heidenreich et al.,
2014), in prostate PDEs is consistent with outcomes of
the TERRAIN and STRIVE clinical trials. As an AR
antagonist, bicalutamide inhibits expression of AR-
regulated genes such as PSA, as well as genes involved
in cellular proliferation, differentiation, and survival
(Furr, 1996; Maucher and von Angerer, 1993). In
TERRAIN and STRIVE, a serum PSA decline of
≥ 50% from baseline was achieved in 31% and 21%
of bicalutamide-treated patients, respectively (Penson
et al., 2016; Shore et al., 2016). In our cohort of PDEs
treated with bicalutamide, a similar rate of PSA
decline was observed, with 25% of PDEs showing
≥ 50% decrease in PSA gene expression compared
with vehicle treatment. PSA increase from baseline
was also observed in a subset of patients in both clini-
cal trials, which was again similar to our results where
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Fig. 4. Modulation of ERa signaling in breast cancer PDEs. (A) qPCR analysis of PGR expression shows differential response to 10 nM E2 in
breast cancer PDEs (n = 14). Samples with ≥ 50% change compared to vehicle were considered responsive. Data are presented as the
mean  SEM. (B) ChIP-sequencing analysis of ERa binding sites in breast cancer PDEs (n = 3), untreated primary breast cancers (n = 3), an
in vivo xenograft tumor grown from the ERa-positive MCF7 cell line, and MCF7 cells cultured in vitro (n = 2). Shown are examples of ERa
binding events that are shared by all models (RARA), present only in in vivo models (SLCO5A1) or present only in cell line models (TOB1/
SPAG9). (C) Venn diagram showing the overlap of ERa binding sites identified in PDEs treated with E2 or E2+ R5020. Only ChIP-seq peaks
identified in at least two tumors were considered included. Heat map of treatment-specific binding events from the Venn diagram. Data
were centered at the top of the peak and visualized with a 5-kb window around the peak. (D) ERa ChIP-seq binding sites identified in E2
or E2+ R5020-treated breast cancer PDEs. Examples of common binding sites (upper panel) and treatment-specific binding (lower panel)
sites are shown.
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PSA increased ≥ 50% compared with vehicle treatment
in 16% of cases.
Ki67 expression is a measure of cells in the active
phase of the cell cycle and is a widely used marker of
proliferating cells (Scholzen and Gerdes, 2000). Ki67
proliferative index is an independent predictor of pros-
tate cancer outcomes (Fisher et al., 2013; Pollack
et al., 2004; Zellweger et al., 2009); however, the wide
range of Ki67 expression naturally observed in clinical
prostate tumors and a lack of consensus on appropri-
ate cutoff points have prevented utilization of Ki67 as
a marker in the clinic (Penault-Llorca and Radosevic-
Robin, 2017). Similarly, we observed wide variation in
baseline Ki67 expression in PDE tissues, reflecting the
diverse genetic heterogeneity of prostate tumors (Bar-
bieri et al., 2013). Further, we observed a positive cor-
relation between Ki67 immunostaining and androgen
signaling in bicalutamide-treated PDEs, consistent
with the effect of bicalutamide on prostate tumor
PDE proliferation being AR-mediated. Despite
observing significant effects of bicalutamide on PDE
proliferative index, apoptotic response to bicalutamide
was also evaluated, using the immunohistochemistry
marker cleaved caspase-3. We have previously
reported apoptosis induction in prostate cancer PDEs
cultured for 48 h with other therapeutic agents (Cen-
tenera et al., 2012). It is therefore likely that higher
doses of bicalutamide than the 10 lM used in this
study are required to induce apoptosis in prostate
cancer PDEs.
Breast cancer is highly heterogeneous, clustering into
10 different molecular subgroups based on an inte-
grated analysis of genomic aberrations and transcrip-
tional profiling (Curtis et al., 2012). Tumors that
express ERa represent the majority (≥ 70%) of all
cases (Curtis et al., 2012). Assessment of ERa and
PGR status by immunohistochemistry guides
treatment decisions for breast cancer, as PGR is an
ERa-regulated gene and used as a biomarker of ERa
activation (Lee and Gorski, 1996). We found that ERa
signaling is not only sustained in breast cancer PDEs,
but that the estrogenic response of ERa-positive PDEs
significantly varies in terms of PGR regulation.
Although an established ERa-regulated gene, PGR
expression at the mRNA level can be influenced by
factors that modulate the transcriptional activity of
ERa (e.g., E2 metabolism, expression of transcrip-
tional cofactors, degree of receptor phosphorylation)
or regulate PGR expression independent of ERa (e.g.,
environmental levels of progesterone, insulin-like
growth factors), reviewed in Ref. (Grimm et al., 2016).
Exposure to exogenous hormones through endocrine
therapy or menopausal hormone therapy is another
factor that affects ERa and PGR status (Ali and
Coombes, 2002). Therefore, the heterogeneity we
observed is likely representative of individual tissue
microenvironments, and the PDE model provides an
avenue to more accurately dissect how the tumor
setting influences ERa signaling. In support of this
concept, we used genomewide profiling of hormone-
treated breast cancer PDEs to capture ERa binding
events and demonstrated reprogramming of ERa bind-
ing by synthetic progestin R5020, a phenomenon we
recently reported using cell line models and clinical
samples (Mohammed et al., 2015; Singhal et al., 2016).
Collectively, our data demonstrate the major advan-
tage of the PDE model, which is the capacity for
quantitative evaluation and comparison of different
pharmacological agents in matched patient material.
Traditionally, within-patient comparisons have only
been possible between pre- and post-treatment samples
from neoadjuvant studies or through utilization of
diagnostic needle biopsies (Beltran et al., 2017).
Obtaining this type of material is notoriously difficult
without direct access to clinical trials or due to the
limited amount of quality tissue available from biopsy
after diagnostics are complete. The utilization of clini-
cal material for profiling the genome, transcriptome,
and proteome has remarkably advanced our under-
standing of the molecular features of breast and pros-
tate cancer. The potential now offered by the PDE
model is -omic analysis of matched treated and
untreated samples using the PDE model. Our teams
have published transcriptomic and proteomic analysis
of PDE tissues (Armstrong et al., 2018; Nguyen et al.,
2018; Pishas et al., 2014), and here, we demonstrate
the added capacity for cistromics. Expanding the
repertoire to include the lipidome, metabolome,
kinome, and secretome will provide further critical
insight into tumor biology and better define the mech-
anism of action of pharmaceutical agents preclinically,
which will lead to the identification of more clinically
relevant therapeutic targets and improved translation
of research findings.
Preclinical models that more accurately represent
human disease are needed to improve translational
cancer research outcomes. The appreciation for
patient-derived models in this context is increasing
rapidly in parallel with organoid and PDX techniques.
The major difference between explant and organoid
culture is that the latter are generated from tumors
that are minced and enzymatically digested to dissoci-
ate cells for seeding in Matrigel (Gao et al., 2014),
whereas explant tissue is cultured in its native format
without disruption to the tissue architecture or tumor
microenvironment. In this way, explants are more
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analogous to PDX models but without the significant
associated costs, timeframes, and complication of infil-
trating mouse stroma (Whittle et al., 2015). Another
disadvantage of PDX models is that the take rate is
biased toward more aggressive tumors such that
engraftment may even be indicative of poor patient
outcome (DeRose et al., 2013). The poor take rate of
primary tumors means that PDX lines do not neces-
sarily represent all disease states. In contrast, tissues
from benign, primary, and advanced disease stages
have been successfully cultured using the PDE tech-
nique with an extremely high take rate that is depen-
dent on the presence of epithelial cells rather than the
aggressiveness of the tumor cells. The PDE method
therefore enables rapid, high-throughput, and cost-
effective analyses of diverse human tumors and disease
stages. We propose that incorporation of the PDE
model into preclinical drug development programs will
facilitate better selection of agents for clinical trials
and provide biological insight into key molecular path-
ways of oncogenesis. The major criterion for imple-
mentation of the PDE model is ready access to fresh
tissue samples, necessitating a strong collaboration
between surgeons, pathologists, and scientists. The reli-
ance on fresh tissue also means that PDEs cannot be
passaged or revived from frozen material. What
remains to be proven over the longer term is whether
this approach can indeed predict in vivo clinical
responses and lead to new, more effective cancer treat-
ments or biomarkers of treatment response. Toward
this goal, a recent study in non-small-cell lung cancer
reported a significant correlation between cisplatin sen-
sitivity in ex vivo cultured tissue and patient survival
(Karekla et al., 2017). Future neoadjuvant clinical
studies comparing pre- and post-treatment tissues to
include parallel ex vivo cultures of the pretreatment
tumor tissues will validate the PDE model using clini-
cally relevant end points. This will provide an exciting
opportunity to investigate novel mechanisms of treat-
ment resistance and identify biomarkers of treatment
response that are essential for the realization of per-
sonalized cancer medicine.
5. Conclusion
PDE culture of breast and prostate tumors is a high-
throughput and cost-effective technique that retains
the tissue’s native architecture, microenvironment, and
key oncogenic drivers. This approach allows direct
within-patient comparison to rapidly evaluate efficacy
of therapeutic agents in a personalized manner and is
amenable to analysis using contemporary molecular
technologies.
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